Aspirin may increase cancer survival by up to 20%


SHAFAQNA- In a new study conducted by Cardiff University, researchers find that taking a low-dose of aspirin can help cancer patients increase their chance of survival by up to 20% and stop their cancer from spreading. The finding is published in the journal PLOS ONE.

Previous research has shown that taking aspirin is of significant benefit in reducing some cancers. However, its role in the treatment of cancer remains uncertain.

To address the issue, researchers conducted a systematic review of the available scientific literature. The data included five randomized studies and 42 observational studies of colorectal cancer, breast cancer and prostate cancer.

Based on the available evidence, the review showed that low-dose aspirin taken by patients with bowel cancer, breast cancer or prostate cancer, in addition to other treatments, was associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.

The results from 6 studies of other cancers also suggest a reduction, but the numbers of patients were too few to enable confident interpretation.

A mutation – known as PIK3CA – was present in about 20% of patients, and appeared to explain much of the reduction in colon cancer mortality by aspirin.

One of the concerns about taking aspirin remains the potential for intestinal bleeding. That’s why researchers specifically looked at the available evidence of bleeding. They also wrote to all authors asking for further data. In no study was serious or life-threatening bleeding reported.

Researchers suggest that there is a desperate need for more detailed research to verify the review and to obtain evidence on less common cancers.

However, they want to urge patients diagnosed with cancer to speak to their doctor about the findings so they can make an informed decision as to whether or not they should take a low-dose aspirin as part of the cancer treatment.

Ref: Knowridge Science

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *